These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 9539496)

  • 1. Rationale and clinical evidence for the use of GP IIb/IIIa inhibitors in acute coronary syndromes.
    Braunwald E; Maseri A; Armstrong PW; Califf RM; Gibler WB; Hamm CW; Simoons ML; Van de Werf F
    Am Heart J; 1998 Apr; 135(4):S56-66. PubMed ID: 9539496
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rationale and clinical evidence for the use of GP IIb/IIIa inhibitors in acute coronary syndromes.
    Braunwald E; Maseri A; Armstrong PW; Califf RM; Gibler WB; Hamm CW; Simoons ML; Van de Werf F
    Eur Heart J; 1998 Apr; 19 Suppl D():D22-30. PubMed ID: 9597519
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Use of platelet glycoprotein IIb/IIIa receptor inhibitors in acute coronary syndrome and coronary intervention].
    Kakuta T; Kishi Y; Numano F
    Nihon Rinsho; 1998 Oct; 56(10):2630-4. PubMed ID: 9796330
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of abciximab in interventional cardiology.
    Chronos N; Vahanian A; Betriu A; Emanuelsson H; Goldberg S; Gulba D; van Hout BA
    Am Heart J; 1998 Apr; 135(4):S67-76. PubMed ID: 9539497
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Platelet inhibitors in non-ST-segment elevation acute coronary syndromes and percutaneous coronary intervention: glycoprotein IIb/IIIa inhibitors, clopidogrel, or both?
    Silva MA; Donovan JL; Gandhi PJ; Volturo GA
    Vasc Health Risk Manag; 2006; 2(1):39-48. PubMed ID: 17319468
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An overview of the results of clinical trials with glycoprotein IIb/IIIa inhibitors.
    Adgey AA
    Am Heart J; 1998 Apr; 135(4):S43-55. PubMed ID: 9539495
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of abciximab in interventional cardiology.
    Chronos N; Vahanian A; Betriu A; Emanuelsson H; Goldberg S; Gulba D; van Hout BA
    Eur Heart J; 1998 Apr; 19 Suppl D():D31-9. PubMed ID: 9597520
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safe use of platelet GP IIb/IIIa inhibitors.
    Ferguson JJ; Kereiakes DJ; Adgey AA; Fox KA; Hillegass WB; Pfisterer M; Vassanelli C
    Am Heart J; 1998 Apr; 135(4):S77-89. PubMed ID: 9539498
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety of glycoprotein IIb-IIIa inhibitors: A heart surgeon's perspective.
    Dyke CM
    Am Heart J; 1999 Oct; 138(4 Pt 2):307-16. PubMed ID: 10502236
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An overview of the results of clinical trials with glycoprotein IIb/IIIa inhibitors.
    Adgey AA
    Eur Heart J; 1998 Apr; 19 Suppl D():D10-21. PubMed ID: 9597518
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safe use of platelet GP IIb/IIIa inhibitors.
    Ferguson JJ; Kereiakes DJ; Adgey AA; Fox KA; Hillegass WB; Pfisterer M; Vassanelli C
    Eur Heart J; 1998 Apr; 19 Suppl D():D40-51. PubMed ID: 9597521
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Platelet glycoprotein IIb/IIIa inhibitors in coronary artery disease].
    Auer J; Berent R; Lassnig E; Weber T; Maurer E; Eber B
    Herz; 2003 Aug; 28(5):393-403. PubMed ID: 12928738
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The clinical use of the GPIIb/IIIa inhibitors eptifibatide and tirofiban in the treatment of acute coronary syndromes of the "non-ST elevation" type].
    Galli M; Maggioni AP; Vassanelli C; Tavazzi L
    Ital Heart J Suppl; 2000 Feb; 1(2):202-11. PubMed ID: 10731377
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The evolving role of platelet glycoprotein IIb/IIIa inhibitors in the management of acute coronary syndromes.
    Stringer KA
    Ann Pharmacother; 1999 Jun; 33(6):712-22. PubMed ID: 10410186
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized trial of an oral platelet glycoprotein IIb/IIIa antagonist, sibrafiban, in patients after an acute coronary syndrome: results of the TIMI 12 trial. Thrombolysis in Myocardial Infarction.
    Cannon CP; McCabe CH; Borzak S; Henry TD; Tischler MD; Mueller HS; Feldman R; Palmeri ST; Ault K; Hamilton SA; Rothman JM; Novotny WF; Braunwald E
    Circulation; 1998 Feb; 97(4):340-9. PubMed ID: 9468207
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent antiplatelet drug trials in the acute coronary syndromes. Clinical interpretation of PRISM, PRISM-PLUS, PARAGON A and PURSUIT.
    Alexander JH; Harrington RA
    Drugs; 1998 Dec; 56(6):965-76. PubMed ID: 9878986
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: pathophysiologic foundation and clinical findings.
    Kleiman NS; Lincoff AM; Ohman EM; Harrington RA
    Am Heart J; 1998 Oct; 136(4 Pt 2 Su):S32-42. PubMed ID: 9778086
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The use of glycoprotein IIb/IIIa inhibitor therapy in acute ST-segment elevation myocardial infarction: current practice and future trends.
    Campbell KR; Ohman EM; Cantor W; Lincoff AM
    Am J Cardiol; 2000 Apr; 85(8A):32C-8C. PubMed ID: 10793178
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Platelet glycoprotein IIb/IIIa receptor inhibition in non-ST-elevation acute coronary syndromes: early benefit during medical treatment only, with additional protection during percutaneous coronary intervention.
    Boersma E; Akkerhuis KM; Théroux P; Califf RM; Topol EJ; Simoons ML
    Circulation; 1999 Nov; 100(20):2045-8. PubMed ID: 10562258
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glycoprotein IIb/IIIa receptor antagonists in the management of cardiovascular diseases.
    Chong PH
    Am J Health Syst Pharm; 1998 Nov; 55(22):2363-86. PubMed ID: 9825033
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.